Invesco’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Invesco’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-62,863	Closed	-$631K	–	3981
2023 Q4	$631K	Sell	62,863 -2,263	-3%	-$10.3K	﹤0.01%	3102
2023 Q3	$188K	Buy	65,126 +1,664	+3%	+$6.08K	﹤0.01%	3610
2023 Q2	$242K	Sell	63,462 -15,209	-19%	-$42.6K	﹤0.01%	3562
2023 Q1	$146K	Buy	+78,671	New	+$164K	﹤0.01%	3670
2022 Q4	–	Sell	-93,907	Closed	-$302K	–	4077
2022 Q3	$302K	Buy	93,907 +352	+0.4%	+$1.15K	﹤0.01%	3511
2022 Q2	$515K	Buy	93,555 +19,443	+26%	+$60.5K	﹤0.01%	3310
2022 Q1	$173K	Buy	74,112 +34,679	+88%	+$118K	﹤0.01%	3796
2021 Q4	$238K	Buy	+39,433	New	+$379K	﹤0.01%	3715

Invesco's GRCL Position: Q1 2024 in Review

Invesco sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 62,863 shares — an estimated $631K sold.

Invesco first reported a position in GRCL in Q4 2021 and held it in 8 quarters. The position peaked at $631K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Invesco reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Invesco sold 62,863 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $631K.
Invesco first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2021 and held it in 8 quarters.
Invesco's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $631K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Invesco's 13F filing for Q1 2024, filed 14 May 2024.